A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE 3, LONG-TERM EXTENSION STUDY TO EVALUATE CONTINUOUS SAFETY AND EFFICACY OF BIIB059 (LITIFILIMAB) IN ADULT PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYT
- Registry ID
- 230LE305
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- BIOGEN MA INCORPORATED
- Start date
- 2024-09-03
- Last update
- 2024-03-11
Conditions
Related clinical trials
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS
- A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS
ERYTHEMATOSUS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF ANIFROLUMAB IN ADULTS WITH CHRONIC AND/OR SUBACUTE
CUTANEOUS LUPUS ERYTHEMATOSUS WHO ARE REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL
THERAPY
- A PHASE 3 PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SLE
- A MULTICENTER, RANDOMIZED, DOSE-BLIND, PHASE 3 LONG-TERM EXTENSION STUDY TO EVALUATEB CONTINUOUS SAFETY AND EFFICACY OF BIIB059 IN ADULT PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB059 IN ADULT PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS RECEIVING BACKGROUND NONBIOLOGIC LUPUS STANDARD OF CARE
View on source registry